PAR 7.69% 21.0¢ paradigm biopharmaceuticals limited..

Chart, page-3633

  1. 11,227 Posts.
    lightbulb Created with Sketch. 705
    Well the whole point of this exercise seemed to be to pump the SP, and not to provide anything meaningful. They would already have known which biomarkers are effected by their drug. But biomarkers are irrelevant if the drug doesn't meet SS in a double blinded Ph 3 trial.

    Maybe somebody will start buying now it is back to base.

    I feel sorry for the bag holders today.

    All IMO
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.